ATP5IF1 and breast carcinoma: Based on our LCC9 and LY2 cell experiments, we would expect that breast cancer patients with endocrine-resistant disease (metastasis) on TAM therapy will have increased miR-29b-1/a which would result in lower ATP5G1 and ATPIF1 transcript levels.